Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Three-Armed, Randomized Phase-III-Study, to Compare the Efficacy, Tolerability and Safety of Three Doses of Mitoxantrone in the Treatment of Patients With Secondary Progressive Multiple Sclerosis

NCT00146159 is registered in ClinicalTrials.gov with Wyeth is now a wholly owned subsidiary of Pfizer as lead sponsor.

NCT NCT00146159
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00146159 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Three-Armed, Randomized Phase-III-Study, to Compare the Efficacy, Tolerability and Safety of Three Doses of Mitoxantrone in the Treatment of Patients With Secondary Progressive Multiple Sclerosis
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Phase
Phase 3
Overall status
Terminated
Start date
March 31, 2005
Completion date
Not reported
Enrollment
336 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

secondary progressive multiple sclerosis